Search 

Genticel is a clinical stage biopharmaceutical company that develops multivalent vaccines for patients infected with Human Papillomavirus (HPV). Till date, the company has raised EUR 27 Mio in funding.

Current investors include Edmond de Rothschild Venture Partners, Innobio Fund, IDInvest (Allianz) and Amundi. 

Our lead investigational vaccine, ProCervix, has successfully finished a very positive data-rich Phase Ib trial on 47 HPV16 and/or 18 infected women. ProCervix is the first therapeutic vaccine offering a solution to the more than 93 million women worldwide already infected with HPV 16 and/or 18 before the appearance of high grade neoplasia. This very large population, exposed at high risk to develop cervical cancer, is only now becoming accessible thanks to new screening guidelines prescribing first line HPV-based testing.

A large survey of prescribers and a Market Access Study predict overwhelming acceptability and a very large market potential.

Genticel wants to take ProCervix into Clinical Phase II and further develop our second product, a heptavalent therapeutic HPV vaccine, up to clinical stage.

To do this, we intend to raise additional capital from our current and selected international investors. 

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

Immune Design is a privately held biotechnology company based in Seattle, Washington and formed in 2008 to bring together some of the world’s leaders in the field of immunology, and their technologies, to develop therapeutic vaccines for the treatment of infectious and malignant disease. The company’s scientific founders are Dr. David Baltimore (Past President of Caltech, Rockefeller University, and the Whitehead Institute and the Co-Recipient of the 1975 Nobel Prize in Physiology or Medicine), Dr. Steven Reed (Past Co-founder and CSO of Corixa and Founder/CEO of the Infectious Diseases Research Institute), and Dr. Larry Corey (President and Director of the Fred Hutchinson Cancer Research Center and Professor of Medicine and Laboratory Medicine at the University of Washington). To date Immune Design has raised approximately $52 million from The Column Group, Alta Partners, Versant Ventures, and Proquest.  
Immune Design leverages its unique vaccine technologies to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response.  The first technology is a novel adjuvant for recombinant protein antigen (rP)-based vaccines comprising Glucopyranosyl Lipid A (GLA), a synthetic TLR4 agonist, formulated in a stable 2% oil-in-water emulsion (SE). Adjuvants can play an important role in vaccine therapies by stimulating the immune system's response to the target antigen. GLA is the first ‘designer adjuvant’ and was developed by Immune Design co-founder Dr. Steve Reed.  To date GLA-SE has been safely administered in over 300 human subjects.   

Our second vaccine platform is a novel lentivirus-based vector, ID-LV (Immune Design-Lentiviral Vector). The prototype of ID-LV was developed by Immune Design co-founder, Dr. David Baltimore. ID-LV is unique in that it can stimulate the body’s own dendritic cells (DCs), the “sentinels” of the immune system, to produce any, and importantly, multiple antigens of interest in the same product configuration, effectively orchestrating the human immune system to respond to targeted diseases.  Immune Design’s ID-LV and GLA-SE vaccine technologies are immunologically synergistic, as documented in animal models, and thus, have the potential to be used both alone and in combination to create the next generation of vaccines for diseases with unmet medical need.

Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The Company’s DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I clinical trials and has demonstrated both safety and immunogenicity potential. Immunovaccine is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company’s delivery technology platform to develop vaccines for livestock.

InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel breakthrough cancer therapies based on the unique functions of its proprietary miRNAs.

InteRNA well equipped to move quickly towards the clinic

InteRNA's drug development programs aim at developing miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis.

InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, which is the largest currently available.

With the Company's proprietary miRNA expression database (generated through deep sequencing) and additional technologies (like RNAseq, PAR-CLIP, bioinformatics, in vivo models) in place to identify the downstream regulated proteins for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their biomarkers quickly towards the clinic.

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees.

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Headquartered in Geneva, Switzerland, NovImmune is a life science enterprise with a proprietary next-generation antibody drug discovery platform and expertise in advancing drug candidates from bench to bedside. The Company is applying its capabilities to realize a vision of generating drugs that provide more robust benefit to patients by attacking the cause rather than symptoms of disease. NovImmune has established a balanced pipeline of first- and best-in-class pre-clinical and clinical drug candidates with a mix of both clinically validated and novel targets.

§  CHF 182M raised from high net worth individuals, private and corporate venture funds

§  In 2009, received the European Biotechnica Award

§  In 2010, established Genentech/Roche partnership for NI-1401, anti-IL-17 drug candidate

§  In 2011, received Orphan Drug designation in Europe and the USA for, and EUR 6 million FP7 grant from the European Commission for development of NI-0501 for HLH

§  In 2012, filing to initiate important clinical studies including the first Phase II study for NI-0501 in HLH, and first-in-man study for leading anti-TLR4 drug candidate, NI-0101

§  Pursuing additional partnerships for its next-generation antibody platform as well as development and commercialization of selected drug candidates

§  Potential to independently bring selected drugs to the market for focused applications

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis.

The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of Ireland’s leading academic institution with a core focus on immunology research. Opsona's lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers. The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.

The Company is supported by an international venture consortium including Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and Enterprise Ireland. Further information is available at http://www.opsona.com/.

ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man. 

Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration.   Founded in 2000, and venture backed from 2002, Oryzon has a strong focus in EPIGENETIC TARGETS with a special emphasis in Histone Lysine Demethylases being a global leader on Lysine Specific Demethylase1. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Two recent papers in NatureMedicine and CancerCELL stablished proof of concept data that support the use of LSD1 inhibitors in acute myeloid leukemia. Oryzon has two preclinical programs with different preclinical candidates LSD1i, one in leukemia and the other in Huntington disease. Phase I/IIa studies are expected to start in early 2013.

In Oncology, we also develop new non invasive early diagnostics tools. Our first product GynEC®-DX consists on a new set of markers for triage in endometrial cancer from uterine aspirates.